linjc16/ctgov huggingface dataset:
1-1-12 Wash-in for Desflurane Low Flow Anesthesia

Study Overview
=================
Brief Summary
-----------------
We propose a new wash-in technique for desflurane low flow anesthesia with fresh gas flow of O2:N2O 1:1 L/min with desfluraene 12%. The objective of this study is to identify time to achieve alveolar concentration of desflurane at1, 2, 3, 4, 5 and 6%.

Detailed Description
-----------------
The benefits of low flow anesthesia are economic, less pollution, more heat and humidity preservation but it requires appropriate wash-in phase. The current wash-in protocols are complicated and time consuming. We propose a new 1-1-12 desflurane wash-in protocol which is more simple and predictable. The objective of this study is to identify time to achieve alveolar concentration of desflurane at 1, 2, 3, 4, 5 and 6% with 1-1-12 wash-in protocol. All patients will receive iv propofol 2 mg/kg as induction agent and succinyl choline 1.5 mg/kg for intubation. Then the ventilation will be controlled to achieve end-tidal CO2 30-35 mmHg with O2:N2O 1:1 L/min with desflurane 12%. Time to achieve alveolar concentration of desflurane at 1, 2, 3, 4, 5 and 6% will be recorded and analyzed. After that, the concentration of desflurane and anesthetic technique will be adjusted to requirement of anesthesiologist.

Official Title
-----------------
1-1-12 Wash-in for Desflurane Low Flow Anesthesia

Conditions
-----------------
Anesthesia

Intervention / Treatment
-----------------
* Procedure: 1-1-12 wash-in


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA classification I-II age 18-64 years Exclusion Criteria: BMI > 35 contraindicated for N2O with pulmonary or cardiac disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 64 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1-1-12 wash-in<br>wash-in using O2:N2O 1:1 L/min with desflurane 12% | Procedure: 1-1-12 wash-in<br>* wash-in phase during start of low flow anesthesia<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time (in second) to achieve alveolar concentration of desflurane 1, 2, 3, 4, 5 and 6% |  | participants will be followed until alveolar concentration of desflurane reaches 6%, as expected of 15 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Heart rate |  | participants will be followed until alveolar concentration of desflurane reaches 6%, as expected of 15 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
low flow anesthesia, wash-in, desflurane
Prevalence of Non-alcoholic Fatty Liver Disease Among Non-obese Obstructive Sleep Apnea by Using Transient Elastography

Study Overview
=================
Brief Summary
-----------------
Obstructive sleep apnea (OSA) and non-alcoholic fatty liver disease (NAFLD) are both common diseases related to metabolic diseases with potential cardiovascular consequences and liver complications respectively. Though studies show OSA may take part in the progression of hepatic steatosis, the independent contribution of OSA on liver fat accumulation is unknown. It is hypothesized that nocturnal intermittent hypoxia from OSA is the main driver of NAFLD in non-obese OSA patients. This study is to assess the effect of OSA on NAFLD in non-obese patients.

Official Title
-----------------
Prevalence of Non-alcoholic Fatty Liver Disease Among Non-obese Obstructive Sleep Apnea by Using Transient Elastography

Conditions
-----------------
Sleep Apnea, Obstructive, Fatty Liver

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: aged 18 years or more Exclusion Criteria: underlying cause of liver disease history of excessive alcoholic consumption (more than 30 g/day for men and 20 g/day for women) secondary causes of hepatic steatosis (such as chronic use of systemic corticosteroids) positive hepatitis B surface antigen, anti-hepatitis C virus antibody, or histological evidence of other concomitant chronic liver diseases.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of subjects found to have fatty liver disease among obese patients with obstructive sleep apnea |  | baseline | 
| Number of subjects found to have fatty liver disease among non-obese patients with obstructive sleep apnea |  | baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of subjects found to have fatty liver disease among obese subjects without obstructive sleep apnea |  | baseline | 
| Number of subjects found to have fatty liver disease among non-obese subjects without obstructive sleep apnea |  | baseline | 
| mesenteric fat thickness by ultrasound scan of all subjects |  | baseline |
Quality of Life in Children Cured of Retinoblastoma

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to assess the quality of life of children who have been cured of retinoblastoma - a malignant eye tumor. The study is questionnaire-based, and uses standardized quality of life assessment tools.

Detailed Description
-----------------
Retinoblastoma is the most common eye tumor of children. It can present in one eye (unilateral) or in both eyes (bilateral). The bilateral form is always hereditary. Retinoblastoma is a highly curable tumor. Using a combination of surgery, chemotherapy, radiation and local treatment modalities to the eye, over 98% of patients are cured. This means that most children diagnosed with retinoblastoma will become long-term survivors. The use of surgery (taking out one eye), chemotherapy, and radiation may be associated with long term side-effects, some of which may have significant impact on the quality of life of the child. In addition, in case where the disease is hereditary, additional psychological issues arise. The aim of our study is to assess, in a comprehensive and standardized fashion, the long term quality of life in children who were treated for retinoblastoma, and who are currently alive and well. The assessment will include the use of questionnaires that assess quality of life, as well as participation in age-appropriate activities. Each child, and his/her parent, will be interviewed and the questionnaires completed. The process will take about one hour for each child. No risk or discomfort to the child is involved.

Official Title
-----------------
Quality of Life in Children Cured of Retinoblastoma

Conditions
-----------------
Retinoblastoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Past treatment for retinoblastoma

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in quality of life |  | Baseline and 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Retinoblastoma, Quality of life
PALS for Nutrition Education

Study Overview
=================
Brief Summary
-----------------
The overall goal of this inquiry is to determine whether PALS is more effective than comparable online resources at educating patients in the outpatient clinic setting about nutrition. Participants will be randomly assigned to view either a PALS article or WebMD article on the same nutrition topic. Participants will then fill out a post-survey to assess knowledge uptake and attitudes regarding healthy eating.

Official Title
-----------------
Can the Patient Activated Learning System (PALS) Serve as a Better Model for Nutrition Education Than Other Online-based Educational Material?

Conditions
-----------------
Nutrition Disorders

Intervention / Treatment
-----------------
* Other: Educational Tool, PALS
* Other: WebMD


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient ≥ 18 years of age. Ability to speak and read in English. Passing the screener - Mini-Mental Status Examination. Patient at WCIMA clinic on Upper East Side of Manhattan, NY. Exclusion Criteria: Non-English speakers Inability to read in English Being younger than 18 Not passing the screener Not a patient at WCIMA clinic on Upper East Side of Manhattan, NY.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm 1 - PALS<br>The Patient Activated Learning System (Palsforhealth.com) | Other: Educational Tool, PALS<br>* The Patient Activated Learning System is a free, health education platform.<br>|
| Experimental: Arm 2 - WebMD<br>WebMD.com | Other: WebMD<br>* WebMD is a widely used educational platform for health information.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Knowledge, as measured by assessment questions on the nutrition information provided |  | Day 1, Immediately after reading article | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| E-health usability, as measured by questions from the Kelly et al. scale | Questions to understand the user's understanding, preference and trust of the information based on a 5-point likert scale with 5 being strongly agree in favor. | Day 1, Immediately after reading article |
Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen

Study Overview
=================
Brief Summary
-----------------
This study is a retrospective analysis of an homogeneous population of patients with aggressive B-cell lymphoma and treated upfront with R-CHOP or R-CHOP like regimens to reassess the prognostic factors and hopefully to identify more accurate prognostic subgroups with a clinical and therapeutical relevance.

Official Title
-----------------
Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen (ProDLBCL)

Conditions
-----------------
B-Cell Lymphomas

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically confirmed newly diagnosed aggressive B-cell lymphoma according to the current World Health Organisation Classification, from 2001 to 2007. Any stage of disease. Treatment with R-CHOP or R-CHOP like regimens (+/- transplant). Age at least 18 years. Availability of tissue biopsy at diagnosis for a possible centralized revision. Availability of data on clinical involvement, laboratory, treatment and follow up. Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cases of aggressive B-cell lymphoma<br>Cases of aggressive B-cell lymphoma diagnosed between 2001 to 2007 in Italy | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Aggressive B-cell lymphoma, R-CHOP
Compression Garments on Hypermobility Type of Ehlers-Danlos Syndrome (CGhEDS)

Study Overview
=================
Brief Summary
-----------------
This study evaluates the effects of wearing a compression garment on the postural balance of patients with hypermobility type of Ehlers-Danlos syndrome, in randomised controlled study.

Official Title
-----------------
Compression Garments Effects on Postural Balance of Patients With Hypermobility Type of Ehlers-danlos Syndrome, a Prospective Study on 40 Patients

Conditions
-----------------
Hypermobility Type Ehlers-Danlos Syndrome

Intervention / Treatment
-----------------
* Other: Rehabilitation
* Device: Compression Garment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥16 years hEDS with the 2017 diagnostic criteria . A normal neurological examination with no sensory disorders, no cerebellar syndrome or vestibular syndrome. An optimal balanced analgesic treatment before inclusion Patients who have not modified their physical treatment (physiotherapy) since 6 months. Exclusion Criteria: Surgery of the lower limb (hip, knee or ankle) Patient having already wear compression garments in the year preceding. Neurological history of sensory , vestibular or cerebellar disorders.

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| group1<br>hEDS treated with rehabilitation only | Other: Rehabilitation<br>* Rehabilitation during 4 weeks<br>|
| group 2<br>hEDS treated with rehabilitation associated to compression garments wearing | Other: Rehabilitation<br>* Rehabilitation during 4 weeks<br>Device: Compression Garment<br>* Rehabilitation associated to wearing CG during 4 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Centre of pression speed | a stability parameter on a force plate | 4 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Compression garment
Retrospective Study on Cenos Stem With BoneMaster HA

Study Overview
=================
Brief Summary
-----------------
Retrospective data collection of the CENOS implant comparing with and without BoneMaster HA coatings.

Detailed Description
-----------------
Not applicable as study was withdrawn

Official Title
-----------------
Retrospective Study on Cenos Stem With BoneMaster HA

Conditions
-----------------
Osteoarthritis

Participation Criteria
=================
Eligibility Criteria
-----------------
Patients Who Received CENOS prosthesis for Intended Uses
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complication Rate |  |  |
Latin America Real World Study With Inspiron Drug Eluting Stent - INSPIRON LATITUDE

Study Overview
=================
Brief Summary
-----------------
Prospective, multicenter, single arm registry to monitor post-market clinical outcomes of patients treated with Inspiron Sirolimus-Eluting Stent with Biodegradable Polymer.

Detailed Description
-----------------
Prospective, multicenter, single arm registry to assess the safety and performance of Inspiron Sirolimus-Eluting Stent with Biodegradable Polymer for the treatment of real world patients.

Official Title
-----------------
LATIn American sTUdy to Investigate the Clinical Performance of Sirolimus-eluting Stent With Abluminal-only bioDEgradable Polymeric Coating (Inspiron TM) in the Treatment of Native Coronary Artery Lesions.

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Device: Angioplasty


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All individuals aged over 18 years who signed the informed consent and had lesions in native coronary arteries treated only with Inspiron Sirolimus-Eluting stent. Exclusion Criteria: Saphenous vein grafts or Mammary lesions; Individuals who have been treated within the last 6 months with another stent; Acute myocardial infarction with ST segment elevation; Chronic Total Occlusion

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Angioplasty|Inspiron Drug Eluting stent implantation|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MACE (major cardiac events) | Major cardiac events (death, myocardial infarction, target vessel revascularization) | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Acute success | Acute success measured by Angiography after stent implantation | up to 24 hours | 
| Stent Thrombosis | Stent Thrombosis rate | 24 months | 
| MACE | Major cardiac events (death, myocardial infarction, target vessel revascularization) | 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
coronary disease, drug eluting stent, Inspiron
Evaluation of the Effects of Certolizumab Pegol on Semen Quality in Healthy Male Volunteers

Study Overview
=================
Brief Summary
-----------------
The primary objective of this study is to evaluate the effect of certolizumab pegol (CZP) on the quality of sperm obtained from healthy male volunteers.

Detailed Description
-----------------
CZP is a PEGylated humanized Fab' fragment with specificity for human tumor necrosis factor alpha (TNFα). Evidence suggests that modulation of TNFα signaling may affect male spermatogenesis. Therefore, this study will compare semen quality parameters before and after a single 400 mg dose of CZP, or matched placebo.

Official Title
-----------------
A Randomized, Single-center, Double-blind, Placebo-controlled Study to Explore the Effect of a Single Dose of Certolizumab Pegol 400 mg on Semen Quality in Healthy Male Volunteers

Conditions
-----------------
Sperm Quality

Intervention / Treatment
-----------------
* Biological: Certolizumab pegol
* Biological: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy male volunteers with normal baseline semen quality parameters Exclusion Criteria: Previous participation in studies involving TNF inhibitors Prior treatment with biologic response modifiers within 5 half-lives History of trauma or surgery to the pelvis/genital area Tests positive for tuberculosis, HIV, Hepatitis B or C

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Placebo<br>0.9% saline | Biological: Placebo<br>* 2 x prefilled syringes containing 0.9% saline, administered once, subcutaneously<br>|
| Experimental: Certolizumab pegol<br>Certolizumab pegol 400 mg | Biological: Certolizumab pegol<br>* 400 mg certolizumab pegol in 2 x 200 mg/mL, prefilled syringes, administered once, subcutaneously<br>* Other names: Cimzia®;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total sperm motility (%) |  | baseline to 99 days | 
| Sperm morphology (%) |  | Baseline to 99 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progressive motility (%) |  | Baseline to 99 days | 
| Non-progressive motility (%) |  | Baseline to 99 days | 
| Sperm vitality (%) |  | Baseline to 99 days | 
| Semen volume (mL) |  | Baseline to 99 days | 
| Sperm count (millions) |  | Baseline to 99 days | 
| Sperm concentration (millions/mL) |  | Baseline to 99 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
certolizumab pegol, Cimzia®, healthy male volunteers, sperm